Scienture Holdings, Inc. (SCNX)
NASDAQ: SCNX · Real-Time Price · USD
0.41755
-0.0014 (-0.32%)
May 29, 2026, 1:23 PM EDT - Market open
Scienture Holdings Revenue
Scienture Holdings had revenue of $56.33K in the quarter ending March 31, 2026, with 449.08% growth. This brings the company's revenue in the last twelve months to $477.68K, up 225.17% year-over-year. In the year 2025, Scienture Holdings had annual revenue of $431.61K with 215.87% growth.
Revenue (ttm)
$477.68K
Revenue Growth
+225.17%
P/S Ratio
35.63
Revenue / Employee
$53,075
Employees
9
Market Cap
16.97M
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 431.61K | 294.97K | 215.87% |
| Dec 31, 2024 | 136.64K | -1.23M | -89.98% |
| Dec 31, 2023 | 1.36M | -8.89M | -86.69% |
| Dec 31, 2022 | 10.25M | 360.77K | 3.65% |
| Dec 31, 2021 | 9.89M | -7.23M | -42.24% |
| Dec 31, 2020 | 17.12M | 9.69M | 130.26% |
| Dec 31, 2019 | 7.44M | 3.60M | 94.07% |
| Dec 31, 2018 | 3.83M | 900.50K | 30.72% |
| Dec 31, 2017 | 2.93M | 449.41K | 18.11% |
| Dec 31, 2016 | 2.48M | -430.66K | -14.79% |
| Dec 31, 2015 | 2.91M | 1.42M | 94.66% |
| Dec 31, 2014 | 1.50M | 540.35K | 56.53% |
| Dec 31, 2013 | 955.88K | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| UnitedHealth Group | 449.71B |
| Johnson & Johnson | 96.36B |
| Eli Lilly and Company | 72.25B |
| AbbVie | 62.82B |
| Moolec Science | 7.83M |
| OSR Holdings | 2.63M |
| Lexaria Bioscience | 368.00K |
| Cocrystal Pharma | 225.00K |
SCNX News
- 11 days ago - SCIENTURE Reports First Quarter 2026 Financial Results and Business Update Highlighted by Significant Revenue Growth and Gross Margin Expansion - GlobeNewsWire
- 22 days ago - Scienture Secures $11.0 Million in Non-Dilutive Debt Financing to Accelerate Growth of Approved Product Portfolio and Advancement of R&D Pipeline - GlobeNewsWire
- 22 days ago - Scienture announces third patent granted for Arbli - TheFly
- 23 days ago - SCIENTURE Announces Third Patent Grant for ARBLI™ (losartan potassium) Oral Suspension, Strengthening Long-Term Market Exclusivity Through 2041 - GlobeNewsWire
- 6 weeks ago - Scienture granted 180-day extension to meet Nasdaq minimum bid price - TheFly
- 2 months ago - SCIENTURE Reports Year End 2025 Financial Results and Provides Business Update - GlobeNewsWire
- 2 months ago - Why Is Scienture Holdings Stock (SCNX) Up Today? - TipRanks
- 2 months ago - Scienture formalized multiple GPO agreements for Rezenopy - TheFly